Xenetic Biosciences, Inc. (XBIO)
NASDAQ: XBIO · Real-Time Price · USD
3.130
+0.100 (3.30%)
At close: Apr 28, 2026, 4:00 PM EDT
3.070
-0.060 (-1.92%)
After-hours: Apr 28, 2026, 4:04 PM EDT

Xenetic Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Revenue
2.982.52.541.711.16
Upgrade
Revenue Growth (YoY)
19.04%-1.56%48.80%47.06%165.64%
Upgrade
Gross Profit
2.982.52.541.711.16
Upgrade
Selling, General & Admin
2.753.423.563.653.74
Upgrade
Research & Development
3.073.293.494.773.16
Upgrade
Operating Expenses
5.816.77.068.426.91
Upgrade
Operating Income
-2.83-4.2-4.52-6.72-5.75
Upgrade
Interest & Investment Income
0.150.250.360.170.1
Upgrade
Other Non Operating Income (Expenses)
0.01-0.010.03-00
Upgrade
EBT Excluding Unusual Items
-2.68-3.96-4.13-6.55-5.65
Upgrade
Pretax Income
-2.68-3.96-4.13-6.55-5.65
Upgrade
Net Income
-2.68-3.96-4.13-6.55-5.65
Upgrade
Net Income to Common
-2.68-3.96-4.13-6.55-5.65
Upgrade
Shares Outstanding (Basic)
22211
Upgrade
Shares Outstanding (Diluted)
22211
Upgrade
Shares Change (YoY)
10.40%0.86%7.44%38.38%60.81%
Upgrade
EPS (Basic)
-1.58-2.57-2.71-4.61-5.49
Upgrade
EPS (Diluted)
-1.58-2.57-2.71-4.61-5.49
Upgrade
Free Cash Flow
-2.29-2.82-4.11-4.65-4.74
Upgrade
Free Cash Flow Per Share
-1.34-1.83-2.69-3.27-4.61
Upgrade
Gross Margin
100.00%100.00%100.00%100.00%100.00%
Upgrade
Operating Margin
-95.23%-168.16%-177.78%-393.57%-495.12%
Upgrade
Profit Margin
-90.07%-158.39%-162.78%-383.87%-486.36%
Upgrade
Free Cash Flow Margin
-76.83%-112.69%-161.98%-272.23%-408.21%
Upgrade
EBITDA
-----5.75
Upgrade
D&A For EBITDA
----0
Upgrade
EBIT
-2.83-4.2-4.52-6.72-5.75
Upgrade
EBIT Margin
-95.23%-168.16%-177.78%--
Upgrade
Revenue as Reported
2.982.52.541.711.16
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.